Bristol-Myers Squibb Company operates in the Healthcare sector, within the Biopharmaceutical industry. Founded in 1887, the company develops, manufactures, and commercializes innovative prescription medicines globally.

Its portfolio is concentrated in high-value therapeutic areas:

• Oncology.

• Immunology.

• Hematology.

• Cardiovascular diseases.

• Neuroscience.

Flagship products include Opdivo and Yervoy in oncology, as well as Eliquis for the prevention of stroke and other thromboembolic conditions.

The company operates internationally, with the United States representing a core revenue market. Bristol-Myers Squibb invests heavily in research and development and maintains partnerships with biotechnology companies and research institutions to expand its clinical pipeline.

Performance is influenced by patent exclusivity cycles, regulatory approvals, pricing policy, competition from generics and biosimilars, and R&D execution.

Bristol-Myers Squibb shares trade on the New York Stock Exchange (NYSE) under the ticker BMY.

History and Development

The company was founded in 1887 by William McLaren Bristol and John Ripley Myers. It expanded throughout the twentieth century, strengthening its presence in specialty pharmaceuticals.

A defining milestone occurred in 1989 with the merger between Bristol-Myers and Squibb Corporation, creating a global biopharmaceutical leader.

In recent years, the company has focused on expanding its pipeline through acquisitions, advancing cardiovascular and oncology therapies, and investing in precision medicine and next-generation biologics, reinforcing its long-term positioning in innovative drug development.

Additional Information

Bristol-Myers Squibb Company (United States) is listed on the NYSE and has a market capitalization of $120.39 billion, with shareholders equity totaling $22.32 billion.

The company employs approximately 30.250 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Bristol-Myers Squibb Company reported $49.19 billion in revenue, generating net income of $9.28 billion.

Key financial metrics include a P/E ratio of 12.97, a price-to-book (P/B) ratio of 5.39, and a trailing twelve-month dividend yield of 4.26%.

The company trades under the ticker BMY.